Non Small Cell Lung Cancer (NSCLC) Clinical Trial
Official title:
Complete Endosonographic Intrathoracic Nodal Staging of Lung Cancer Patients in Whom Stereotactic Ablative Radiotherapy (SABR), is Considered
Rationale: Accurate staging of lung cancer is important because it directs treatment and
determines prognosis. The development of Stereotactic Ablative Radiotherapy (SABR), has
revolutionized radiation therapy for early stage lung cancer and results demonstrate similar
outcomes in comparison to surgical resection of the lung tumor. The staging work-up program
for patients with a potentially resectable Non-Small-Cell Lung Cancer (NSCLC) includes at
least a computed tomography (CT) scan of the chest and integrated Positron Emission
Tomography - Computed Tomography (PET/CT) scans, and when indicated, invasive mediastinal
staging. However, patients who are treated with SABR do not routinely undergo the same nodal
staging work-up as do surgical candidates. As both surgery and SABR appear to achieve
comparable rates of local and regional tumor control, it appears only logical to perform a
similar staging work-up in all patients with early stage lung cancer who will be treated
with either of the two curative local modalities. In the past, a lack of invasive nodal
sampling before SABR was considered acceptable as invasive surgical staging
(mediastinoscopy) was widely considered the preferred procedure. However, with minimally
invasive and safe endosonography procedures now available, improved pre-treatment staging
has become possible for patient groups who are eligible for SABR, including those with
significant comorbidities.
Hypothesis: Complete endosonographic (combined endobronchial and esophageal) staging of
hilar and mediastinal lymph nodes in patients with (suspected) non-small cell lung cancer
(NSCLC) will result in change of loco-regional nodal status in 20% of patients, in
comparison to staging by PET-CT alone.
Study population: Patients with either established or suspected early-stage NSCLC who are
medically inoperable, or who refuse surgery but are potential candidates for SABR with
curative intent (provided no intrathoracic metastases are present). Patients will undergo a
single scope complete mediastinal and hilar staging procedure (combined EndoBronchial
UltraSound (EBUS) and Transesophageal Endoscopic Ultrasound with EBUS scope (EUS-B)).
Status | Recruiting |
Enrollment | 102 |
Est. completion date | |
Est. primary completion date | June 2017 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Proven, or highly suspected, non-small cell lung cancer (NSCLC) - Absence of distant metastases based on PET-CT - Stereotactic ablative radiotherapy (SABR) with curative intent is contemplated - One of the following features based on PET-CT: - Centrally located clinical T1-T2 N0 tumor - Peripheral located clinical T2 N0 tumor - Suspicion of N1- N2 disease based on either size (short axis > 10mm CT) or FDG uptake - Non-FDG avid primary lung tumor and lymph nodes Exclusion Criteria: - Medically operable patients with a resectable lung tumor (unless SABR is the explicit preference of the patients or treating physicians preference). - Bulky nodal disease based on PET-CT - Contra-indications for endosonography and / or bronchoscopy - Pregnancy - Age under 18 - No informed consent |
Observational Model: Cohort, Time Perspective: Prospective
Country | Name | City | State |
---|---|---|---|
Netherlands | NKI-AvL | Amsterdam | |
Netherlands | VUMC | Amsterdam | |
Netherlands | UMCN | Nijmegen | |
Poland | Independent Endoscopy Unit, John Paul II Specialist Hospital | Krakow |
Lead Sponsor | Collaborator |
---|---|
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) |
Netherlands, Poland,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Proportion of patients with change in nodal status based on imaging compared to nodal status based on endosonography. | Prior to endoscopy the nodal status (single outcome measure either N0,N1,N2,N3) will be defined based on (PET) CT imaging. After complete endosonographic staging (EBUS+EUS-B) of the hilus and mediastinum again the nodal status will be defined (single outcome measure either N0,N1,N2,N3) based on endosonography findings. The sensitivities, negative predictive values (NPV) and positive predictive values (PPV) for endosonography and PET-CT imaging will be calculated. |
0-6 months | No |
Secondary | Radiotherapy plan based on imaging (prior to endosonography) compared to the radiotherapy plan based on endosonography outcomes. | The radiotherapist will make a radiation plan (Gross Tumor Volume (GTV) primary tumor, internal target volume (ITV) primary tumor and planning target volume (PTV) primary tumor) based on (PET) CT imaging prior to endosonography. After endosonography the radiotherapist will make another radiotherapy plan based on endosonography staging results. The proportions of changed radiotherapy plans per patient basis will be calculated. | 1 month | No |
Secondary | Incremental pathological confirmation of the diagnosis of lung cancer in patients with only a clinical diagnosis, following endosonographic staging. | 1 month | No | |
Secondary | Complication rate of a complete endosonographic procedure in this patients group | 1 month | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01204099 -
Study of PX-866 and Docetaxel in Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT04083599 -
GEN1042 Safety Trial and Anti-tumor Activity in Subjects With Malignant Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT00148798 -
Study of Cisplatin/Vinorelbine +/- Cetuximab as First-line Treatment of Advanced Non Small Cell Lung Cancer (FLEX)
|
Phase 3 | |
Recruiting |
NCT06026410 -
KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
|
Phase 1 | |
Completed |
NCT02988817 -
Enapotamab Vedotin (HuMax-AXL-ADC) Safety Study in Patients With Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT01005797 -
Study of Panobinostat in Combination With Sorafenib in Kidney, Soft Tissue or Lung Cancers
|
Phase 1 | |
Recruiting |
NCT00637910 -
Tarceva Italian Lung Optimization tRial
|
Phase 3 | |
Active, not recruiting |
NCT03447678 -
Pembrolizumab in First Line Treatment of Advanced NSCLC Patients With PD-L1 Low Tumors.
|
Phase 2 | |
Completed |
NCT02456246 -
Piloting the Feasibility of FLT-PET/CT Non-Small Cell Lung Cancer Managed With SBRT
|
N/A | |
Terminated |
NCT01741155 -
Study of SPI-1620 in Combination With Docetaxel Versus Docetaxel Alone for Patients With Non Small-cell Lung Cancer (NSCLC)
|
Phase 2 | |
Completed |
NCT02014324 -
Single Scope Staging of Lung Cancer With Endosonography
|
N/A | |
Completed |
NCT01594398 -
Study to Assess Food Effect on Pharmacokinetics of Entinostat in Subjects With Breast Cancer or Non-Small Cell Lung Cancer
|
Phase 1 | |
Completed |
NCT01323062 -
Bavituximab Plus Carbo and Pemetrexed in Chemo-Naive Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Subjects
|
Phase 1 | |
Active, not recruiting |
NCT04772989 -
A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies
|
Phase 1 | |
Completed |
NCT01702844 -
Single Arm on the Tolerability of Weekly Nab-paclitaxel
|
Phase 2 | |
Completed |
NCT00492206 -
Study of Cetuximab With Radiation Followed by Consolidation Chemotherapy for NSCLC
|
Phase 2 | |
Completed |
NCT00820417 -
Pharmocokinetic/Pharmacodynamic (PK/PD) Study of the Combination Cetuximab/Gefitinib
|
Phase 1 | |
Completed |
NCT02639026 -
Trial Of Hypofractionated Radiotherapy In Combination With MEDI4736 And Tremelimumab For Patients With Metastatic Melanoma And Lung, Breast And Pancreatic Cancers
|
Phase 1 | |
Completed |
NCT01282437 -
Prophylactic Cranial Irradiation (PCI) vs Observation in Stage III NSCLC
|
Phase 3 | |
Active, not recruiting |
NCT04721015 -
Study of Intravenous (IV) ABBV-637 Alone or in Combination With IV Docetaxel/Osimertinib to Assess Adverse Events and Change in Disease Activity in Adult Participants With Relapsed/Refractory (R/R) Solid Tumors
|
Phase 1 |